Oregon Administrative Rules Chapter 925 - DEPARTMENT OF CONSUMER AND BUSINESS SERVICES, PRESCRIPTION DRUG AFFORDABILITY BOARD
Oregon Administrative Rules Chapter 925 — Department of Consumer and Business Services, Prescription Drug Affordability Board
Overview and Purpose
OAR Chapter 925 contains the administrative rules establishing the Prescription Drug Affordability Board (PDAB) within Oregon’s Department of Consumer and Business Services (DCBS). The PDAB was created by Oregon legislation (notably Senate Bill 844 in 2021) to address the rising cost of prescription drugs by promoting affordability and transparency.
Mission of the PDAB
Primary mission: To monitor and evaluate the costs of prescription drugs in Oregon and to recommend policies and regulations aimed at reducing excessive drug prices.
To protect consumers from unaffordable prescription drugs.
To promote transparency in drug pricing and supply chain.
To regulate drug price increases that exceed affordability thresholds.
Structure and Key Provisions of OAR Chapter 925
Establishment and Governance
The Board consists of appointed members with expertise in public health, consumer advocacy, pharmacy, economics, and health insurance.
Rules govern appointment, terms, and responsibilities of Board members.
Drug Pricing Review and Affordability Thresholds
The PDAB evaluates drug prices and price increases.
Rules define thresholds for when a drug price or price increase is considered "unjustified" or "excessive."
The Board can set upper payment limits or maximum allowable prices for certain drugs.
Data Collection and Reporting
Pharmaceutical companies, insurers, and pharmacy benefit managers (PBMs) must report pricing data and supply chain costs.
Reporting rules specify deadlines, data formats, confidentiality, and penalties for noncompliance.
Hearings and Appeals
Procedures for hearings if manufacturers or stakeholders dispute Board findings or pricing decisions.
Appeals process under Oregon’s Administrative Procedure Act (APA).
Enforcement and Penalties
The Board has authority to impose civil penalties for violations of pricing rules or reporting requirements.
Procedures for imposing and contesting penalties.
Public Transparency and Education
The Board must publish reports on drug pricing trends.
Education initiatives to inform consumers and policymakers.
Legal Context and Important Case Law
1. Statutory Authority
The PDAB’s authority under OAR Chapter 925 is rooted in the Oregon legislature’s enactment of laws aimed at drug price regulation and consumer protection.
The Board’s rules must conform to enabling statutes, especially regarding limits on pricing authority and procedural fairness.
2. Administrative Law and Due Process
Oregon’s Administrative Procedure Act requires that:
The PDAB provide notice and opportunity for hearing before imposing penalties or pricing limits.
Decisions be supported by substantial evidence.
Board actions not be arbitrary or capricious.
Courts reviewing PDAB decisions focus on procedural regularity and adherence to statutory mandates.
3. Case Example: Hypothetical PharmaCorp v. PDAB
Although specific cases involving the PDAB may still be emerging due to the Board’s recent establishment, hypothetical challenges illustrate key issues:
A pharmaceutical company may argue that a pricing limit constitutes an unlawful regulatory taking under the Oregon Constitution.
Courts typically balance the government’s interest in protecting public health and affordability against private property rights.
Early precedents from other states regulating drug prices suggest courts will uphold reasonable price controls if procedurally fair and justified by evidence.
4. First Amendment Considerations
Drug manufacturers may challenge reporting and transparency rules on grounds of compelled speech or commercial free speech.
Courts weigh the government’s interest in transparency and consumer protection against free speech rights.
Precedents generally uphold disclosure requirements if they are factual, non-misleading, and serve a substantial governmental interest.
5. Interstate Commerce and Federal Preemption
PDAB’s regulations may face challenges based on the Commerce Clause if they unduly burden interstate commerce.
Federal law, including the Food, Drug, and Cosmetic Act and Medicare/Medicaid statutes, may preempt some state regulation.
Courts analyze whether PDAB rules conflict with federal law or frustrate federal regulatory objectives.
Summary and Impact of OAR Chapter 925
OAR Chapter 925 operationalizes Oregon’s legislative intent to combat high drug prices through regulation and transparency.
The PDAB acts as a regulatory watchdog, empowered to impose limits on unjustified drug prices.
The rules ensure procedural fairness, data transparency, and enforcement mechanisms.
Legal challenges focus on constitutional protections, administrative fairness, and federal preemption.
This represents a novel and evolving area of law at the intersection of health policy, administrative law, and constitutional rights.
RELATED Blog
0 comments